Is WAY a buy according to AI stock analysis?

WAY AI stock analysis does not label the stock a universal buy because while Waystar delivered a strong Q2 2026 beat with 18% revenue growth, a 43% adjusted EBITDA margin, and a cheap forward multiple, the stock is still below its 200-day moving average, shares outstanding rose 8.52% year over year, a law firm is investigating the company, and GAAP trailing earnings are thin. Investors should treat the page as a research framework and compare Waystar growth, bookings, net retention, dilution, and valuation with their own risk limits.

What is the WAY AI stock forecast?

The WAY AI stock forecast uses a scenario range of roughly $16 to $55 rather than a precise target. The bullish case needs sustained non-GAAP EPS growth near 18% with AI-enabled bookings and subscription momentum; the bearish case becomes more likely if growth decelerates, volume-based revenue stagnates, dilution continues, or the Kaskela investigation escalates. Analyst price targets cluster between $25 and $44 with a $33.22 average.

What technical levels matter for WAY?

The most important WAY technical levels are the $20.68 to $21 support zone near the 50-day moving average of $20.78, the $26.51 to $26.73 resistance zone where the 38.2% retracement meets the 200-day moving average, and the $17.26 June low. The stock trades above its 50-day average but below its 200-day average after the Q2 2026 rebound, so confirmation of a trend change requires a reclaim of the 200-day with volume.

Can AI predict WAY stock price?

No, AI cannot reliably predict stock prices. AI can organize Waystar filings, Q2 2026 results, subscription and volume-based revenue, net retention, bookings, valuation math, chart levels, and risk scenarios, but it cannot know future healthcare payment utilization, AI competition timelines, the outcome of the Kaskela investigation, contract renewals, or changes in investor sentiment toward healthcare technology.

How should I use this WAY AI trading strategy?

Use this WAY AI trading strategy as a checklist for trend confirmation, mean-reversion planning, risk controls, and fundamental monitoring. It is not personalized advice, and every setup should be checked against fresh quotes, position sizing, stop conditions, the August 25, 2026 Investor Day, the next earnings report, and new company disclosures including any investigation developments.

What could make the Waystar stock thesis fail?

The Waystar thesis could fail if AI-native billing tools commoditize the RCM platform faster than expected, if the Iodine cross-sell ramp stalls, if volume-based utilization stays near 3% growth, if rising share count erodes per-share value, if the Kaskela investigation escalates into material claims, or if GAAP profitability fails to scale from the current thin base.

Waystar Holding Corp. research snapshot

WAY AI Stock Analysis

WAY AI stock analysis as of the August 3, 2026 data cutoff reads Waystar Holding Corp. as a cloud-based healthcare payment software and revenue cycle management (RCM) platform that connects providers, payers, and patients and processes more than 7.5 billion transactions annually for about 30,000 clients and over 1 million providers. At the August 3, 2026 data cutoff, WAY traded near $22.00, up 4.22% from the $21.11 July 31 close, with an independently verified market capitalization of about $4.22 billion. The Q2 2026 report, released July 29, 2026, delivered revenue of $319.7 million, up 18% year over year and above the $316.17 million consensus, a non-GAAP diluted EPS of $0.43 versus the $0.40 consensus, a 43% adjusted EBITDA margin, a net revenue retention rate of 108%, and a raised full year 2026 outlook including revenue of $1.276 billion to $1.294 billion and non-GAAP diluted EPS of $1.61 to $1.70. The stock still trades below its 200-day moving average after a broad decline from the September 2025 high near $41.47, with share count up 8.52% year over year and short interest near 7.09% of shares outstanding. The WAY AI stock forecast uses scenarios, not a single price prediction, and treats subscription revenue growth, volume-based utilization, AI-enabled bookings, net retention, dilution, and the pending Kaskela Law investigation as the key variables. This page is an informational research tool, not investment advice.

Current price

$22.00 at the August 3, 2026 market open reading, up 4.22% from the $21.11 July 31 close, after opening at $22.04

Market cap

$4.22 billion, computed as $22.00 x 191.75 million shares and reported by StockAnalysis.com

AI score

58 / 100

Rating

High-growth healthcare payment software with strong bookings and a cheap forward multiple, offset by share dilution, a pending law firm investigation, and a stock still below its 200-day average

Trend status

Recovering after a Q2 2026 earnings beat, above the 50-day average near $20.78, still below the 200-day average near $26.73, and down about 39% over the trailing 52 weeks

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Waystar has SEC filings, a quarterly earnings release and call, StockAnalysis and Barchart market data, coverage from 24 to 26 analysts, and strong operating metric disclosure such as NRR, client counts, and AI share of bookings. However, it IPO'd in June 2024, so the public history is short and some long-term comparisons require forward inference.
bias Check: The main AI research bias is over-crediting the strong Q2 2026 beat and the 18% revenue growth while underweighting the roughly 39% one-year stock decline, the 8.52% year-over-year increase in shares outstanding, the 7.09% short interest, the Kaskela Law shareholder investigation, and the fact that volume-based revenue grew only 3% year over year. The reverse check asks why the market still prices WAY at a low forward multiple despite a raised outlook: the answer is that GAAP earnings are thin on a trailing basis, shares are being diluted, organic subscription growth is about 12% versus the 34% headline, and investors are waiting to see whether the high-growth subscription and AI booking mix converts into durable GAAP profitability.
ai Confidence: High for reported Q2 2026 figures, the raised guidance, market cap math, balance sheet figures, and valuation ratios that cross-validated across StockAnalysis.com, Barchart, the Q2 2026 earnings release, and the Q2 2026 earnings call during the August 3, 2026 refresh. Medium for forward price scenarios because the AI booking mix, volume-based utilization, Iodine cross-sell ramp, and the outcome of the shareholder investigation are less visible from public data.
investment Certainty: Medium-low. Waystar has real growth, strong bookings, a healthy 108% net revenue retention, and a cheap forward multiple, but investment certainty is lower than data confidence because shares are being diluted, the stock is still in a broad downtrend below its 200-day average, a law firm is investigating the company, and the GAAP earnings base is still thin relative to the non-GAAP story.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Waystar sells cloud-based healthcare payment and RCM software that helps providers get paid faster and more accurately. Revenue is recurring and the model is highly scalable: Q2 2026 revenue grew 18% year over year, subscription revenue grew 34% (organic 12%), and adjusted EBITDA margin was 43%.	Medium-high
Moat	The moat comes from transaction scale (7.5 billion transactions and $2.4 trillion in gross claims annually), switching costs from deeply embedded RCM workflows, proprietary payment data, EHR and clearinghouse integration depth, and an emerging AI advantage via AltitudeAI and Iodine. It is real but not absolute, because large health systems can build or buy competing capability and AI-native entrants are lowering the cost of building billing automation.	Medium-high
Management	CEO Matt Hawkins and the team delivered a ninth consecutive quarter of revenue and EBITDA beats, raised guidance, and grew clients above $100,000 of annual revenue by 15% year over year to 1,453. CFO Steve Oreskovich transitioned out after eight years and Alpana Wegner became CFO on August 1, 2026, a key-person transition to monitor.	Medium
Financial trend	Q2 2026 revenue was $319.7 million, up 18%, with GAAP net income of $40.9 million, non-GAAP net income of $83.3 million, adjusted EBITDA of $136.7 million at a 43% margin, and unlevered free cash flow of $63.9 million. TTM revenue is about $1.21 billion with TTM GAAP net income of $134.79 million, but shares outstanding rose 8.52% year over year.	High
Valuation	At $22.00, financial_rigor.py and StockAnalysis.com agree on about 31x trailing GAAP earnings, roughly 13x forward non-GAAP earnings, 1.02x to 1.06x book value, about 16x to 17x free cash flow, and about 3.4x to 3.5x revenue. The forward multiple is cheap for a software platform growing revenue near 17%, but the trailing GAAP multiple is elevated and dilution limits per-share value creation.	High
Technical trend	WAY trades above its 50-day moving average near $20.78 but below its 200-day moving average near $26.73, with RSI near 49.85 in neutral territory. The stock is up from a June 22, 2026 low of $17.26 but remains in a broad downtrend from the September 2025 high near $41.47.	Medium
Risk level	Risk is medium-high. Key risks are share dilution, the Kaskela Law investigation, GAAP earnings thinness, dependence on a small number of large platform clients for bookings, volume-based revenue growth of only 3%, AI competition, healthcare regulation, and the volatility of a recently public company with a short earnings history.	High
AI confidence	Descriptive confidence is high because filings and third-party datasets agree on Q2 2026 results, the raised guidance, balance sheet figures, and valuation math. Forward-return confidence is lower because the stock decline, dilution, and the shareholder investigation suggest the market sees risks that are not fully visible in the trailing financials.	High data confidence
Investment certainty	Waystar is a fast-growing, cash-generating healthcare payments platform with strong bookings, but certainty is lower than data confidence because the stock is below its 200-day average, shares are being diluted, a law firm is investigating the company, and the valuation multiple needs sustained execution to re-rate.	Medium-low

WAY AI stock forecast

WAY AI Stock Forecast Scenarios

The WAY AI stock forecast should be read as a scenario range, not a price promise. Using the $22.00 price reference at the August 3, 2026 data cutoff, the FY2026 non-GAAP EPS consensus of about $1.66, and the audited three-year model, the mechanical range points to roughly $49 in a bullish case, $30 in a base case, and $16 in a bearish case before considering further dilution. Analyst price targets cluster between $25 and $44 with a $33.22 average, broadly consistent with the base-to-bull path.

Bullish case

$44 to $55

More likely if Waystar sustains roughly 18% annual non-GAAP EPS growth through subscription momentum, AI-enabled bookings near 40% of the mix, Iodine cross-sell, and net retention above 108%, while the market re-rates the stock toward the 18x forward multiple and the shareholder investigation resolves without material impact.

Base case

$28 to $34

More likely if Waystar grows non-GAAP EPS around 12% annually in line with the FY2026 guidance, subscription growth stays in the mid-teens on an organic basis, volume-based revenue recovers to the long-term 1% to 2% utilization trend, and the stock holds near the current 13x forward multiple, which aligns with the $33.22 average analyst target.

Bearish case

$14 to $19

More likely if growth decelerates below the guidance midpoint, volume-based revenue stagnates, client concentration on large platform deals causes lumpy bookings, the share count keeps rising, the Kaskela investigation escalates, or the market compresses WAY toward a 9x forward multiple on concerns about GAAP profitability and AI competition.

WAY AI technical analysis

WAY AI Technical Analysis

WAY AI technical analysis is neutral-to-cautious as of the August 3, 2026 data cutoff. StockAnalysis.com showed WAY near $22.00, up 4.22% from the $21.11 July 31 close, above the 50-day moving average near $20.78, below the 200-day moving average near $26.73, with RSI near 49.85 and a 52-week range of $17.26 to $41.47. Barchart reported a 24% sell technical opinion with a weak short-term outlook but noted relative strength just crossed above 50%. The stock recovered from a June 22, 2026 low of $17.26 after the Q2 2026 beat, but remains in a broad downtrend and needs to reclaim the 200-day average to confirm a trend change.

Level	Value	Why it matters
Current price	$22.00	StockAnalysis.com real-time quote at the August 3, 2026 market open reading, up 4.22% from the $21.11 July 31 close, after opening at $22.04.
50-day moving average	$20.78	StockAnalysis.com reported the 50-day moving average near $20.78 on August 3, 2026. The stock holds above it, which is a mild short-term positive after the earnings rebound.
200-day moving average	$26.73	StockAnalysis.com reported the 200-day moving average near $26.73. Regaining and holding this level would be the first confirmation of a trend change.
Near support	$20.68 to $21	Barchart listed first support near $20.68 on August 3, 2026, close to the 50-day average. A close below this zone would put the rebound at risk.
Secondary support	$19.44 to $20.26	Barchart listed second and third support levels near $20.26 and $19.44. A break below would open the path toward the June low.
52-week low	$17.26	Established June 22, 2026. A test of this level matters for measuring downside extension if the rebound fails.
Near resistance	$22.75 to $23.18	Barchart listed second and third resistance levels near $22.75 and $23.18 on August 3, 2026. A close above would confirm follow-through from the earnings rebound.
Fibonacci retracement	$26.51 (38.2%), $29.37 (50%), $32.22 (61.8%)	Barchart retracement levels off the $41.47 high to the $17.26 low. The 38.2% level at $26.51 sits just below the 200-day average and is the first major recovery target.
Momentum	Neutral RSI near 50	RSI near 49.85 is neutral. Barchart noted relative strength just crossed above 50%, a mild positive, but the broad trend is still down.
Volume	Monitor for accumulation	Average 20-day volume is about 2.57 million shares. Look for above-average volume on up days as confirmation of accumulation after the earnings rebound.
Volatility	Elevated monitoring priority	Barchart reported implied volatility near 57% with an expected move of about $2.42 (10.95%) for the next 18 days, reflecting high event-driven volatility for a healthcare IT stock.
Invalidation	Close below $20.68	A decisive close below the $20.68 support zone would invalidate the short-term rebound and suggest a retest of the June low near $17.26.

WAY AI trading strategy

WAY AI Trading Strategy Framework

The WAY AI trading strategy below is a rules-based framework for scenario planning and risk control, not personal advice. It connects price action with subscription growth, volume-based utilization, net revenue retention, AI-enabled bookings, Iodine cross-sell, the pending investigation, and the August 25, 2026 Investor Day catalyst.

Trend-following setup

If WAY reclaims and holds above the $26.51 to $26.73 zone (38.2% retracement and 200-day moving average) with volume confirmation, the trend has a better chance of turning. Pair the signal with sustained subscription growth, net retention at or above 108%, and no material negative news from the shareholder investigation.

A failed reclaim that falls back below the 50-day average near $20.78, or a close below $20.68, can be used as a rules-based stop point. Size positions so that a gap down on investigation or earnings news stays within your risk budget.

Mean-reversion setup

If WAY pulls back toward the $20.68 to $21 support zone without a fundamental break (no revenue guidance cut, no negative investigation development, no major client loss), compare price stabilization with subscription bookings, net retention, and utilization trends. A reversal candle with above-average volume near support can be studied.

Do not average down. The setup invalidates on a close below $20.68, and the position should be sized for a potential retest of the $17.26 June low.

Fundamental monitor

Track quarterly revenue growth, non-GAAP EPS, subscription versus volume-based revenue, net revenue retention, clients above $100,000 of annual revenue, AI share of bookings, share count, free cash flow, and net leverage. Key catalysts include the Investor Day on August 25, 2026 and the next earnings report around November 4, 2026.

The stock can gap sharply on earnings, investigation news, healthcare policy, or AI competition headlines. Use wider position bands during earnings season and keep the investigation outcome on the watchlist.

Investment research summary

Four-master Research Compression

Business essence

Waystar sells cloud-based software that helps healthcare providers get paid faster, more accurately, and at a lower cost to collect. Providers, including hospitals, health systems, physician groups, and payers, pay because the platform automates claims, eligibility, denials, patient payments, and revenue cycle workflows that were previously manual and error-prone. The model is mission-critical, data-rich, and recurring.

Moat

The moat comes from transaction scale (7.5 billion transactions and $2.4 trillion in gross claims annually), integration depth with EHR and clearinghouse workflows, provider and payer switching costs, proprietary payment data, and an emerging AI advantage through AltitudeAI and the Iodine clinical data acquisition. It is real because replacing a deeply embedded RCM platform is disruptive for a health system, but it is not absolute because large providers can build or buy competing capability and AI reduces the cost of building billing automation.

Munger risk inversion

The thesis fails if AI-native tools make Waystar platform capabilities commoditized, if the Iodine cross-sell ramp stalls, if large platform deals create lumpy bookings, if volume-based utilization stays near 3% growth, if the rising share count erodes per-share value, if the Kaskela investigation escalates into material claims, or if GAAP profitability fails to scale from the current thin base.

Management

CEO Matt Hawkins has led nine consecutive quarters of revenue and EBITDA beats, raised 2026 guidance, and emphasized an autonomous revenue cycle vision with AI embedded and monetized across the platform. The CFO transition from Steve Oreskovich to Alpana Wegner, effective August 1, 2026, is the main management event to monitor, along with the $200 million buyback authorized in May 2026 with $13 million repurchased in Q2 at an average of $19.24.

Industry trend

Healthcare RCM benefits from the secular shift toward value-based care, consumerization of healthcare payments, growing billing complexity, and provider pressure to lower the cost to collect. Providers are consolidating fragmented point solutions onto connected platforms, which favors Waystar, while AI-native entrants, EHR vendors adding RCM modules, and large health IT consolidators create competitive pressure.

Valuation and margin of safety

At about $4.22 billion in verified market value and $5.34 billion enterprise value, WAY trades at roughly 13x forward non-GAAP earnings, which is not expensive for a software platform guiding to 17% revenue growth. The margin of safety depends on whether the high subscription and AI booking mix converts into durable GAAP earnings and whether dilution and the shareholder investigation are fully reflected at the current price.

Source-backed data

WAY Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
WAY price	$22.00	StockAnalysis.com real-time quote on August 3, 2026	August 3, 2026
Market capitalization	$4.22 billion, verified from $22.00 x 191.75M shares (0.04% deviation)	StockAnalysis.com and financial_rigor.py verification	August 3, 2026
Enterprise value	$5.34 billion	StockAnalysis.com statistics	August 3, 2026
TTM revenue	$1.21 billion	StockAnalysis.com financials	August 3, 2026
Q2 2026 revenue	$319.7 million, up 18% year over year, above the $316.17M consensus	Waystar Q2 2026 earnings release, July 29, 2026	August 3, 2026
Q2 2026 non-GAAP diluted EPS	$0.43 versus the $0.40 consensus	Waystar Q2 2026 earnings release and Q2 2026 earnings call	August 3, 2026
GAAP net income (TTM)	$134.79 million	StockAnalysis.com statistics	August 3, 2026
Diluted EPS (TTM)	$0.70	StockAnalysis.com statistics	August 3, 2026
Free cash flow (TTM)	$246.26 million	StockAnalysis.com cash flow statement	August 3, 2026
Cash and short-term investments	$191.6 million (cash $12.65M plus investment securities $178.95M)	StockAnalysis.com balance sheet and Q2 2026 earnings call	August 3, 2026
Total debt	$1,482 million (gross debt about $1.5 billion on the earnings call)	StockAnalysis.com balance sheet and Q2 2026 earnings call	August 3, 2026
Net leverage	2.5x as of June 30, 2026, down from 2.7x at the end of Q1 2026	Waystar Q2 2026 earnings call	August 3, 2026
Net revenue retention	108%, within the historical 108% to 110% range	Waystar Q2 2026 earnings release and earnings call	August 3, 2026
FY2026 guidance (raised)	Revenue $1.276B to $1.294B, adjusted EBITDA $535M to $545M, non-GAAP diluted EPS $1.61 to $1.70	Waystar Q2 2026 earnings release, July 29, 2026	August 3, 2026
52-week range	$17.26 to $41.47	StockAnalysis.com statistics	August 3, 2026
Analyst consensus	Strong Buy, average price target $33.22, range $25 to $44, 24 analysts	StockAnalysis.com forecast page (S&P Global)	August 3, 2026
Valuation math	31x trailing GAAP EPS, 13x forward non-GAAP EPS, 16x to 17x P/FCF, 1.02x to 1.06x P/B, 3.4x to 3.5x P/S	StockAnalysis.com statistics and financial_rigor.py verification	August 3, 2026

Frequently Asked Questions

Read the UNH AI stock analysis View CI AI stock forecast Compare HQY AI technical analysis Build a rules-based AI trading strategy

This WAY AI stock analysis is for informational and educational use only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 3, 2026 and can be wrong if fundamentals, competition, the Kaskela investigation, healthcare regulation, AI technology shifts, or investor sentiment change.